<?xml version="1.0" encoding="UTF-8"?>
<p>Trachoma studies have demonstrated that azithromycin MDA leads to selection for macrolide resistance in some organisms, including 
 <italic>Streptococcus pneumoniae</italic>
 <sup>
  <xref rid="b19" ref-type="bibr">19</xref>–
  <xref rid="b22" ref-type="bibr">22</xref>
 </sup> and 
 <italic>Escherichia coli</italic>.
 <sup>
  <xref rid="b23" ref-type="bibr">23</xref>–
  <xref rid="b25" ref-type="bibr">25</xref>
 </sup> However, resistance selection in the most commonly used therapeutic antibiotic classes for childhood infection in sub-Saharan Africa (penicillins and sulfamethoxazole) has generally not been found.
 <sup>
  <xref rid="b6" ref-type="bibr">6</xref>,
  <xref rid="b19" ref-type="bibr">19</xref>,
  <xref rid="b21" ref-type="bibr">21</xref>
 </sup> Trachoma programs distribute millions of doses of azithromycin annually,
 <sup>
  <xref rid="b26" ref-type="bibr">26</xref>
 </sup> of which approximately 15% are administered to children of ages 6 months to 5 years. Health districts are targeted for a predetermined number of years (1, 3, or 5) determined by the baseline prevalence of clinical signs of trachoma children.
</p>
